Gaithersburg, Maryland – August 29, 2018 – MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. On September 5, 2018, at 2:45 p.m. ET, she will speak at the 11th Annual International Partnering Conference BioPharm America™ (Hynes Convention Center, Boston). In October, she will present at the Cell & Gene Meeting on the Mesa, which takes place October 3-5, 2018 in La Jolla, California.
Ms. Bowes will discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies. She will highlight how MaxCyte’s breakthrough CARMA platform in immuno-oncology has the ability to engineer transient persistence to mitigate off-tumor toxicity and significantly reduce the turnaround time of autologous cell therapy to patients.
“It’s exciting to have the opportunity at two important industry conferences to share the progress we’ve made in advancing our novel and proprietary mRNA-based CARMA platform and CAR therapy drug candidates,” said Ms. Bowes. “Our CARMA platform’s approach has potential in a broad range of targets and cancers, including solid tumors. Our novel CAR construct is engineered to reduce potential adverse events that have been evident with previous CAR technologies. This is significant, now more than ever, as we recently received investigational new drug (IND) clearance from the US Food and Drug Administration to begin a clinical study in the United States with our first wholly-owned CAR therapeutic candidate, MCY-M11, and our goal is to advance into the clinic before the end of the year.”
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
|For further information, please contact: